# Seminar 08: Substance Use Disorders ## Year 3: Psychiatry Clerkship --- ## Learning Objectives By the end of this seminar, students will be able to: 1. Diagnose substance use disorders using DSM-5 criteria 2. Recognize intoxication and withdrawal syndromes 3. Apply evidence-based treatments for alcohol use disorder 4. Describe medications for opioid use disorder 5. Manage acute withdrawal safely 6. Apply motivational interviewing principles --- ## Seminar Outline ### I. Overview of Substance Use Disorders Substance use disorders represent a category of conditions characterized by a problematic pattern of substance use leading to clinically significant impairment or distress. The prevalence of substance use disorders is substantial, with approximately ten to twelve percent of the adult population meeting criteria for any substance use disorder in the past year. Alcohol use disorder affects approximately fourteen to fifteen percent of adults over their lifetime, representing the most prevalent substance use disorder. Opioid, cannabis, and stimulant use disorders each affect one to five percent of the population depending on the substance and population studied. Nicotine dependence affects over twenty percent of adults and carries enormous medical morbidity. The DSM-5 diagnostic criteria for substance use disorders incorporate eleven criteria organized into four domains: impaired control, social impairment, risky use, and pharmacological criteria. Impaired control includes using more substance or for longer than intended, unsuccessful efforts to cut down, spending excessive time obtaining, using, or recovering from the substance, and craving or strong urges to use. Social impairment includes failure to fulfill major role obligations, continued use despite interpersonal problems, and reduction of important activities due to use. Risky use includes use in physically hazardous situations and continued use despite knowledge of physical or psychological problems caused by the substance. Pharmacological criteria include tolerance and withdrawal. Severity is determined by the number of criteria met: two to three criteria indicates mild, four to five indicates moderate, and six or more indicates severe substance use disorder. The spectrum approach reflects the continuous nature of problematic substance use rather than the artificial dichotomy of previous diagnostic systems. Specifiers indicate whether the disorder is in early remission, meaning no criteria have been met for at least three months but less than twelve months, sustained remission meaning no criteria have been met for twelve months or longer, or on maintenance therapy. The in a controlled environment specifier applies when the individual is in a setting that restricts substance access. The neurobiology of addiction involves the brain's reward circuitry, particularly the mesolimbic dopamine pathway projecting from the ventral tegmental area to the nucleus accumbens. Substances of abuse produce supraphysiological dopamine release that exceeds natural rewards, hijacking the reward system and creating powerful learned associations between substance use, cues, and reward. Repeated use produces neuroadaptations including tolerance, requiring more substance for the same effect, and sensitization of craving and stress responses. Glutamate systems contribute to learning and memory processes underlying craving and relapse. The prefrontal cortex, which mediates executive function and inhibitory control, shows impaired function in addiction, contributing to loss of control over use. Panel A: A bar graph showing prevalence of various substance use disorders in the general population. Panel B: A diagram of the eleven DSM-5 criteria organized by the four domains of impaired control, social impairment, risky use, and pharmacological. Panel C: A severity spectrum showing mild, moderate, and severe categories with criterion counts. Panel D: A schematic of the reward pathway showing VTA, nucleus accumbens, and prefrontal cortex with dopamine release. --- ### II. Alcohol Use Disorder Screening for alcohol use disorder should be performed routinely in clinical settings given the high prevalence and substantial health impact. The AUDIT questionnaire comprises ten items assessing consumption, symptoms, and consequences and provides comprehensive assessment. The abbreviated AUDIT-C uses only the three consumption questions and performs well as a brief screen. The CAGE questionnaire asks about attempts to Cut down, Annoyance at criticism, Guilt about drinking, and need for an Eye-opener drink. A single question asking about heavy drinking episodes in the past year has also shown good screening performance. Positive screens should prompt more comprehensive assessment. Alcohol intoxication produces effects that vary with blood alcohol level and tolerance. At low levels around zero point zero five percent, mild euphoria and disinhibition occur. At zero point one percent, impaired coordination, judgment, and reaction time become evident. At zero point two percent, marked ataxia and confusion develop. At zero point three percent, stupor occurs with decreased responsiveness. At levels of zero point four percent and above, coma and respiratory depression pose immediate mortality risk. Tolerance can result in functional impairment at lower levels in naive drinkers and preserved function at levels that would be severely intoxicating in non-tolerant individuals. Medical complications of chronic alcohol use affect virtually every organ system. Hepatic complications progress from fatty liver through alcoholic hepatitis to cirrhosis, which carries complications including portal hypertension, variceal bleeding, hepatic encephalopathy, and hepatocellular carcinoma. Gastrointestinal complications include pancreatitis, gastritis, and malabsorption. Neurological complications include peripheral neuropathy, Wernicke encephalopathy characterized by confusion, ataxia, and ophthalmoplegia, and Korsakoff syndrome characterized by anterograde amnesia and confabulation resulting from thiamine deficiency. Cardiovascular complications include cardiomyopathy and arrhythmias. Cancer risk is elevated for oral, esophageal, liver, and breast cancers. Wernicke-Korsakoff syndrome represents a particularly important complication given its preventability and the severity of permanent deficits if untreated. Wernicke encephalopathy is an acute condition caused by thiamine deficiency, presenting with the classic triad of confusion, ataxia, and ophthalmoplegia, though the full triad is often absent. Korsakoff syndrome represents permanent damage resulting in profound anterograde amnesia with relatively preserved other cognitive functions and confabulation. Prevention requires thiamine supplementation for all patients with alcohol use disorder, particularly before glucose administration which can precipitate Wernicke encephalopathy in thiamine-depleted patients. Treatment of suspected Wernicke encephalopathy requires high-dose intravenous thiamine. Panel A: A comparison of alcohol screening tools showing AUDIT, AUDIT-C, CAGE, and single question with performance characteristics. Panel B: A chart showing blood alcohol levels and corresponding clinical effects. Panel C: A diagram of medical complications of alcohol organized by organ system. Panel D: A clinical features comparison of Wernicke encephalopathy versus Korsakoff syndrome with treatment. --- ### III. Alcohol Withdrawal Alcohol withdrawal follows a predictable timeline and can range from mild symptoms to life-threatening complications. Minor withdrawal symptoms including tremor, anxiety, diaphoresis, nausea, and tachycardia typically begin six to twelve hours after the last drink. Alcoholic hallucinosis, involving visual hallucinations typically with intact sensorium, may occur at twelve to twenty-four hours. Withdrawal seizures, typically generalized tonic-clonic, occur most commonly at twenty-four to forty-eight hours and may be the first sign of withdrawal in some patients. Delirium tremens, the most severe form of withdrawal, typically peaks at forty-eight to ninety-six hours after the last drink. Delirium tremens represents a medical emergency characterized by delirium with global confusion, hallucinations, severe autonomic instability including fever, tachycardia, and hypertension, and agitation. The mortality rate is five to fifteen percent even with treatment and higher without treatment. Risk factors for delirium tremens include prior history of delirium tremens or withdrawal seizures, heavy and prolonged alcohol use, older age, concurrent medical illness, and elevated blood alcohol level at presentation. Patients at high risk require intensive monitoring and aggressive treatment. Intensive care unit admission is often necessary for severe cases. The Clinical Institute Withdrawal Assessment for Alcohol, Revised, or CIWA-Ar, provides standardized assessment of withdrawal severity to guide treatment. The scale assesses ten domains including nausea and vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation. Each item is scored from zero to seven, with orientation scored zero to four, yielding a total possible score of sixty-seven. Scores below ten indicate minimal withdrawal, ten to fifteen indicate mild withdrawal, fifteen to twenty indicate moderate withdrawal, and above twenty indicate severe withdrawal. Symptom-triggered treatment guided by CIWA-Ar scores reduces total benzodiazepine dose and treatment duration compared to fixed-schedule dosing. Treatment of alcohol withdrawal relies primarily on benzodiazepines, which provide cross-tolerance with alcohol through shared GABA receptor effects. Chlordiazepoxide and diazepam are long-acting agents that allow for smoother withdrawal with self-tapering. Lorazepam is preferred in patients with hepatic impairment due to absence of active metabolites and can be given parenterally. Symptom-triggered protocols administer benzodiazepines based on CIWA-Ar scores, typically giving medication for scores above eight or ten. Fixed-schedule protocols provide regular dosing with gradual taper. Thiamine should be given to all patients with alcohol withdrawal before glucose. Phenobarbital may be used as an adjunct in refractory cases. Treatment duration typically spans three to seven days. Panel A: A timeline showing alcohol withdrawal symptom progression from minor withdrawal through seizures to delirium tremens. Panel B: A clinical features and management guide for delirium tremens. Panel C: A diagram of the CIWA-Ar scale domains with scoring interpretation. Panel D: A comparison of benzodiazepine treatment protocols showing symptom-triggered versus fixed-schedule approaches. --- ### IV. Medications for Alcohol Use Disorder Naltrexone is a mu-opioid receptor antagonist that reduces the rewarding effects of alcohol and decreases craving. Available as oral tablets dosed at fifty milligrams daily or as monthly extended-release intramuscular injection at three hundred eighty milligrams, naltrexone has demonstrated efficacy in reducing heavy drinking days and increasing abstinence rates. The medication is particularly effective in patients who have already achieved some abstinence and in those with strong cravings. Contraindications include current opioid use due to risk of precipitated withdrawal and acute hepatitis. Common side effects include nausea, headache, and dizziness. Patients should be warned that attempting to override the opioid blockade with high doses of opioids risks respiratory depression. Acamprosate modulates glutamate neurotransmission and is thought to reduce the protracted withdrawal state that contributes to relapse. Dosed at six hundred sixty-six milligrams three times daily, acamprosate has shown efficacy in maintaining abstinence in patients who have already stopped drinking. The medication is renally excreted and contraindicated in severe renal impairment with creatinine clearance below thirty. The main side effect is diarrhea. Acamprosate may be particularly useful in patients with liver disease given the absence of hepatic metabolism. The medication requires consistent adherence to the three-times-daily dosing regimen. Disulfiram inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde when alcohol is consumed, producing an aversive reaction with flushing, nausea, vomiting, and tachycardia. The threat of this reaction provides deterrent effect rather than addressing the underlying pathophysiology of addiction. Disulfiram is dosed at two hundred fifty to five hundred milligrams daily and requires at least twelve hours after the last drink before starting. The medication is most effective when administration is supervised and when patients are highly motivated. Patients must be carefully educated about the reaction and warned to avoid hidden alcohol sources including certain medications and foods. Disulfiram is contraindicated in patients with cardiac disease and is used with caution in hepatic impairment. Additional medications with evidence for alcohol use disorder include gabapentin, which may be particularly helpful in patients with anxiety, insomnia, or craving, typically dosed at up to eighteen hundred milligrams daily in divided doses. Topiramate has shown efficacy in reducing heavy drinking, dosed at titration up to three hundred milligrams daily, though side effects including cognitive impairment limit tolerability. Baclofen has some evidence and may be useful in patients with liver disease. Ondansetron may benefit patients with early-onset alcohol use disorder. None of these medications are FDA-approved for alcohol use disorder, but they represent reasonable options when first-line agents are ineffective or contraindicated. Panel A: A comparison of naltrexone formulations showing oral versus injectable with dosing and clinical considerations. Panel B: A pharmacology profile of acamprosate showing mechanism, dosing, contraindications, and optimal patient selection. Panel C: A diagram of the disulfiram-alcohol reaction with patient education points. Panel D: A second-line medications chart showing gabapentin, topiramate, and others with evidence levels. --- ### V. Opioid Use Disorder The opioid epidemic has produced dramatic increases in opioid-related morbidity and mortality, making recognition and treatment of opioid use disorder a public health priority. Overdose deaths involving opioids have increased substantially, driven initially by prescription opioids, then heroin, and most recently by illicitly manufactured fentanyl and its analogs. Fentanyl is approximately fifty to one hundred times more potent than morphine, and its presence in the illicit drug supply has resulted in markedly increased overdose risk. The contamination of other substances including stimulants with fentanyl has expanded overdose risk beyond individuals who intend to use opioids. Any individual using illicit substances is now at risk for opioid overdose. Opioid intoxication produces characteristic signs including euphoria, drowsiness, miosis or pinpoint pupils, and most dangerously, respiratory depression. Overdose presents with decreased level of consciousness, respiratory rate below twelve breaths per minute, and pinpoint pupils. Death from opioid overdose results from respiratory arrest. Naloxone, an opioid receptor antagonist, rapidly reverses opioid effects and is life-saving when administered during overdose. Naloxone is available in intranasal and intramuscular formulations suitable for layperson administration and should be provided to all patients at risk for opioid overdose and their family members. The brief duration of naloxone relative to longer-acting opioids may require repeated dosing. Opioid withdrawal is intensely uncomfortable but not life-threatening, in contrast to alcohol and sedative withdrawal. Symptoms begin six to twelve hours after the last short-acting opioid use and include anxiety, muscle aches, lacrimation, rhinorrhea, yawning, piloerection or gooseflesh, sweating, diarrhea, nausea, vomiting, dilated pupils, and insomnia. Peak symptoms occur at twenty-four to seventy-two hours for short-acting opioids and later for longer-acting agents. The Clinical Opiate Withdrawal Scale or COWS provides standardized assessment of withdrawal severity. Though not medically dangerous, the severity of withdrawal drives continued use and poses significant barrier to treatment initiation. Treatment of opioid withdrawal may use opioid agonist therapy or symptomatic management. Buprenorphine can be initiated once withdrawal is established, typically at COWS score of eight to twelve or higher, providing both withdrawal relief and ongoing treatment. Methadone similarly provides agonist-mediated withdrawal management. Clonidine, an alpha-2 adrenergic agonist, reduces sympathetic symptoms including anxiety, tachycardia, and sweating but does not address all withdrawal symptoms and is less effective than opioid agonist treatment. Symptomatic medications including loperamide for diarrhea, nonsteroidal anti-inflammatory drugs for pain, and ondansetron for nausea provide adjunctive relief. Medically supervised withdrawal alone without transition to ongoing treatment is associated with high relapse rates and should generally be followed by medications for opioid use disorder. Panel A: A timeline showing the evolution of the opioid epidemic through prescription opioids, heroin, and fentanyl waves. Panel B: A clinical features comparison of opioid intoxication versus overdose with naloxone administration protocol. Panel C: A diagram of opioid withdrawal timeline showing symptom onset and peak. Panel D: A treatment algorithm for opioid withdrawal showing agonist versus symptomatic approaches. --- ### VI. Medications for Opioid Use Disorder Buprenorphine is a partial mu-opioid agonist that provides the cornerstone of office-based treatment for opioid use disorder. The ceiling effect on respiratory depression provides improved safety compared to full agonists. Formulations include sublingual tablets and films, often combined with naloxone to deter injection, as well as extended-release subcutaneous injection. Induction typically requires waiting until the patient is in mild to moderate withdrawal to avoid precipitated withdrawal, then administering initial doses of two to four milligrams with supplemental doses until withdrawal is controlled. Maintenance doses typically range from eight to twenty-four milligrams daily. Following federal regulatory changes, buprenorphine for opioid use disorder can now be prescribed by any provider with a DEA registration, removing the previous X-waiver requirement. Methadone is a full mu-opioid agonist available for opioid use disorder only through licensed opioid treatment programs. Daily observed dosing is required initially, with earned take-home doses for patients demonstrating stability. Typical maintenance doses range from sixty to one hundred twenty milligrams daily, with higher doses associated with better retention and outcomes. Methadone has extensive evidence demonstrating reduction in illicit opioid use, infectious disease transmission, criminal activity, and mortality. Risks include respiratory depression especially during induction, QTc prolongation requiring ECG monitoring, and sedation. The structured program requirements provide support for some patients while creating barriers for others. Naltrexone blocks opioid effects through mu-receptor antagonism, preventing the rewarding effects of opioid use. Available as oral tablets dosed at fifty milligrams daily or extended-release intramuscular injection at three hundred eighty milligrams monthly, naltrexone requires complete opioid abstinence for seven to ten days before initiation to avoid precipitated withdrawal. This requirement creates a significant barrier to treatment initiation, as many patients relapse before completing the required abstinence period. Once initiated, particularly the injectable formulation, naltrexone demonstrates efficacy in preventing relapse. The medication is most effective for highly motivated patients with strong support systems who can successfully navigate the initiation period. Harm reduction strategies complement treatment medications and aim to reduce negative consequences of substance use without requiring abstinence. Naloxone distribution to patients with opioid use disorder, their family members, and the broader community reduces overdose deaths and should be universally implemented. Needle and syringe exchange programs reduce transmission of HIV and hepatitis C while providing contact points for treatment engagement. Fentanyl test strips allow users to detect fentanyl contamination in their drug supply. Safe consumption sites, where implemented, provide supervised settings for drug use with staff trained in overdose response. Low-barrier treatment models minimize requirements for treatment entry to maximize engagement. These approaches prioritize keeping people alive and healthy even if they are not yet ready for or able to achieve abstinence. Panel A: A detailed profile of buprenorphine showing formulations, induction protocol, maintenance dosing, and prescribing regulations. Panel B: A comparison of methadone treatment showing program structure, dosing, efficacy, and risks. Panel C: A naltrexone for opioid use disorder guide showing formulations, initiation requirements, and optimal patient selection. Panel D: A harm reduction framework showing naloxone distribution, syringe exchange, and low-barrier treatment principles. --- ### VII. Other Substance Use Disorders Stimulant use disorders involving cocaine, amphetamine, and methamphetamine produce significant morbidity but lack FDA-approved medications, making treatment primarily behavioral. Intoxication produces euphoria, hypervigilance, increased energy, tachycardia, hypertension, and dilated pupils. Severe intoxication or overdose may produce hyperthermia, seizures, cardiac arrhythmias, myocardial infarction, and stroke. Psychiatric manifestations include agitation, paranoia, and psychosis that may persist beyond acute intoxication. Management of acute intoxication is supportive, with benzodiazepines for agitation and cooling for hyperthermia. Stimulant withdrawal produces a crash with fatigue, hypersomnia, and depression but is not medically dangerous. Cannabis use disorder has increased in prevalence as potency has increased and perception of risk has decreased. Intoxication produces euphoria, impaired memory, slowed reaction time, increased appetite, and conjunctival injection. Heavy use can produce a withdrawal syndrome characterized by irritability, anxiety, insomnia, decreased appetite, and restlessness. Cannabis use may trigger or exacerbate psychotic disorders in vulnerable individuals and is associated with cognitive impairment with heavy adolescent use. No medications are FDA-approved for cannabis use disorder, and treatment is primarily behavioral. Sedative, hypnotic, and anxiolytic use disorders involve benzodiazepines, barbiturates, and Z-drugs and require particular attention due to dangerous withdrawal. The withdrawal syndrome resembles alcohol withdrawal and may include seizures and delirium. Management requires gradual taper with a long-acting benzodiazepine, typically over weeks to months depending on duration and dose of use. Abrupt discontinuation is dangerous and should be avoided. Prevention requires careful prescribing practices including limiting duration of benzodiazepine prescriptions and avoiding prescribing in patients with substance use disorder history. Tobacco use disorder and nicotine dependence contribute to enormous medical morbidity as the leading preventable cause of death. First-line medications for smoking cessation include nicotine replacement therapy available in patch, gum, lozenge, inhaler, and nasal spray formulations, varenicline which is a partial nicotinic receptor agonist and the most effective single agent, and bupropion. Combination therapy with nicotine patch plus short-acting nicotine formulation or varenicline plus nicotine replacement may increase quit rates. Brief counseling and behavioral support enhance medication efficacy. Electronic cigarettes remain controversial as a cessation tool given concerns about long-term safety and potential gateway effects. Panel A: A clinical features and management guide for stimulant intoxication and overdose. Panel B: A cannabis use disorder profile showing intoxication, withdrawal, and treatment considerations. Panel C: A sedative withdrawal management protocol showing taper principles and timeline. Panel D: A smoking cessation algorithm showing first-line medications and combination approaches. --- ### VIII. Assessment and Motivational Interviewing Comprehensive substance use assessment should characterize the pattern and severity of use across all substance classes. History should include substances used, routes of administration, quantities, frequency, duration of use, and patterns of use including triggers and contexts. Consequences across medical, psychiatric, social, occupational, legal, and financial domains indicate severity. Treatment history including what has been tried and with what results guides current planning. Readiness for change should be assessed, as this influences treatment approach. Collateral information from family members or medical records provides valuable perspective. The stages of change model describes the typical progression through which individuals move when changing addictive behavior. Precontemplation describes individuals not considering change, who may be unaware of or minimizing problems. Contemplation describes ambivalent individuals who recognize problems but are not committed to change. Preparation involves planning for change, often setting quit dates or researching treatment options. Action involves actively making changes, including engaging in treatment. Maintenance involves sustaining changes over time. Relapse, while not desirable, is common and represents return to earlier stages rather than treatment failure. Treatment approaches should be matched to stage of change. Motivational interviewing is a patient-centered counseling approach designed to elicit and strengthen motivation for change. The core principles include expressing empathy through reflective listening, developing discrepancy between current behavior and patient values or goals, rolling with resistance rather than arguing, and supporting self-efficacy and the patient's own ability to change. The OARS skills form the foundation: Open-ended questions that invite exploration, Affirmations that acknowledge patient strengths and efforts, Reflective listening that demonstrates understanding and highlights change talk, and Summarizing that synthesizes the conversation and reinforces motivations for change. Brief interventions applying motivational interviewing principles in healthcare settings have demonstrated effectiveness in reducing hazardous alcohol use. Screening, Brief Intervention, and Referral to Treatment, or SBIRT, provides a framework for implementation in primary care, emergency departments, and hospital settings. Screening identifies individuals with risky use. Brief intervention, typically five to fifteen minutes, provides feedback on screening results, advice to reduce use, and enhancement of motivation using motivational interviewing techniques. Referral to treatment connects individuals with substance use disorders to appropriate specialty care. SBIRT represents an evidence-based approach that can be integrated into routine clinical practice. Panel A: A comprehensive assessment framework showing domains to assess in substance use evaluation. Panel B: A circular diagram of the stages of change model with clinical implications for each stage. Panel C: A motivational interviewing principles and OARS skills guide with examples. Panel D: A SBIRT implementation model showing screening, brief intervention, and referral components. --- ### IX. Treatment Settings and Approaches Levels of care for substance use disorder treatment range from brief intervention through intensive residential treatment, with appropriate level determined by severity, safety concerns, and prior treatment response. Outpatient treatment involves weekly or less frequent sessions suitable for stable patients with good support. Intensive outpatient programs provide nine or more hours weekly and allow patients to maintain work and family responsibilities while receiving structured treatment. Partial hospitalization provides twenty or more hours weekly with daily programming. Residential treatment provides twenty-four-hour structured environment for patients needing more intensive support. Medically managed inpatient treatment addresses acute medical or psychiatric needs including severe withdrawal. Behavioral treatments for substance use disorders include multiple evidence-based approaches. Cognitive behavioral therapy identifies triggers and develops coping skills to manage cravings and high-risk situations. Contingency management provides tangible rewards, typically vouchers or prizes, for objective evidence of abstinence such as negative drug tests, with strong evidence particularly for stimulant use disorders. Twelve-step facilitation prepares patients for engagement in Alcoholics Anonymous, Narcotics Anonymous, or similar mutual support groups. Community reinforcement approach restructures the environment to make abstinence more rewarding than substance use. Family therapy involves family members in treatment and addresses family dynamics. Mutual support groups including Alcoholics Anonymous, Narcotics Anonymous, and SMART Recovery provide peer-based support that complements professional treatment. Alcoholics Anonymous and related twelve-step programs follow a spiritual framework emphasizing powerlessness over addiction, reliance on a higher power, and peer fellowship. Research demonstrates that AA participation is associated with increased abstinence rates and is as effective as professional treatment for some individuals. SMART Recovery provides a cognitive-behavioral alternative without spiritual components for individuals who prefer a different approach. Mutual support programs are widely available, free, and provide ongoing community support that professional treatment cannot fully replicate. Special populations require adapted treatment approaches. Treatment during pregnancy should prioritize maternal and fetal health, with medications for opioid use disorder being standard of care for pregnant women with opioid use disorder given the risks of untreated addiction and withdrawal. Adolescents benefit from family-involved treatment and may be less appropriate for adult-focused programs. Co-occurring psychiatric disorders require integrated treatment addressing both conditions simultaneously. Individuals in the criminal justice system benefit from treatment, with diversion and treatment-based approaches more effective than incarceration alone. Cultural considerations should inform treatment engagement and delivery. Panel A: A levels of care framework showing treatment intensity from outpatient through residential with placement criteria. Panel B: A comparison of evidence-based behavioral treatments showing CBT, contingency management, and twelve-step facilitation. Panel C: A mutual support options comparison showing AA, NA, and SMART Recovery with features of each. Panel D: A special populations treatment guide showing adaptations for pregnancy, adolescents, and co-occurring disorders. --- ### X. Complications, Recovery, and Prognosis Medical complications of substance use disorders extend beyond the direct effects of substances to include infectious diseases, trauma, and consequences of injection drug use. Injection drug use carries risk of HIV, hepatitis C, endocarditis, and soft tissue infections including abscesses and necrotizing fasciitis. Screening for HIV and hepatitis C should be routine. Sexually transmitted infections are elevated in individuals with substance use disorders. Overdose represents the most immediate life-threatening complication, with opioid overdose deaths being particularly prominent in the current epidemic. Chronic medical conditions including cardiovascular disease, liver disease, and pulmonary conditions occur at elevated rates. Psychiatric comorbidity is the rule rather than the exception in substance use disorders, with the majority of individuals meeting criteria for additional psychiatric diagnoses. Depression and anxiety disorders are highly prevalent, though distinguishing primary psychiatric disorders from substance-induced symptoms can be challenging. Assessment during a period of abstinence helps clarify the diagnosis. Post-traumatic stress disorder is common, particularly among women with substance use disorders. Attention-deficit/hyperactivity disorder is overrepresented, particularly in stimulant use disorder. Psychotic symptoms may be substance-induced or reflect primary psychotic disorders. Integrated treatment addressing both substance use and psychiatric disorders produces better outcomes than sequential treatment. Recovery from substance use disorder is best understood through a chronic disease model rather than an acute illness framework. Like diabetes or hypertension, addiction involves ongoing management rather than cure, with relapse representing a common complication of a chronic condition rather than treatment failure. Recovery encompasses not just abstinence but broader improvements in health, well-being, and social functioning. The SAMHSA definition emphasizes recovery as a process of change through which individuals improve health and wellness, live self-directed lives, and strive to reach their full potential. Recovery capital, encompassing personal, social, and community resources that support recovery, predicts outcomes and represents a target for intervention. Prognosis varies considerably based on multiple factors. Medications for opioid use disorder reduce mortality by fifty percent or more and represent life-saving treatment. Longer duration of treatment is associated with better outcomes across treatment modalities. Engagement in mutual support enhances outcomes. Strong social support and recovery capital predict success. Comorbid psychiatric disorders, if untreated, worsen outcomes. Multiple prior treatment episodes may indicate treatment-resistant illness but also reflect the chronic relapsing nature of addiction. Brain recovery continues over months to years of abstinence, with gradual normalization of reward and executive function circuitry supporting sustained recovery over time. Panel A: A medical complications diagram showing infectious disease, overdose, and organ system effects. Panel B: A psychiatric comorbidity prevalence chart with guidance for distinguishing primary from substance-induced disorders. Panel C: A chronic disease model comparison showing addiction management alongside diabetes and hypertension. Panel D: A prognostic factors framework showing protective and risk factors for recovery outcomes. --- ## Summary - DSM-5 substance use disorder criteria include eleven criteria across impaired control, social impairment, risky use, and pharmacological domains; severity by criterion count - Alcohol withdrawal progresses from tremor and anxiety through hallucinations, seizures, to delirium tremens; treat with benzodiazepines and thiamine - Wernicke encephalopathy presents with confusion, ataxia, and ophthalmoplegia from thiamine deficiency; give thiamine before glucose - AUD medications include naltrexone to reduce craving, acamprosate to maintain abstinence, and disulfiram for aversive deterrent - Opioid overdose causes respiratory depression with pinpoint pupils; treat with naloxone which all at-risk patients should have - Medications for opioid use disorder include buprenorphine in office-based practice, methadone through opioid treatment programs, and naltrexone requiring opioid abstinence - Motivational interviewing uses OARS skills: Open questions, Affirmations, Reflective listening, and Summarizing - Stages of change include precontemplation, contemplation, preparation, action, and maintenance - Harm reduction strategies including naloxone distribution and needle exchange save lives and engage people in care - Recovery is a long-term process; MOUD reduces mortality by fifty percent or more in opioid use disorder --- ## Key Terms | Term | Definition | |------|------------| | Tolerance | Need for increased amounts of substance to achieve desired effect or diminished effect with same amount | | Withdrawal | Characteristic syndrome occurring when substance use is reduced or stopped | | Craving | Strong desire or urge to use a substance | | MOUD | Medications for Opioid Use Disorder including buprenorphine, methadone, and naltrexone | | Harm reduction | Strategies to reduce negative consequences of substance use without requiring abstinence | | CIWA-Ar | Clinical Institute Withdrawal Assessment for Alcohol, Revised; standardized withdrawal severity scale | | Delirium tremens | Severe alcohol withdrawal with delirium, autonomic instability, and potential mortality | | Motivational interviewing | Patient-centered counseling approach to elicit and strengthen motivation for change | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*